Axon Enterprise, Inc $AXON Shares Sold by Andra AP fonden

Andra AP fonden lessened its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 11.9% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 20,176 shares of the biotechnology company’s stock after selling 2,721 shares during the quarter. Andra AP fonden’s holdings in Axon Enterprise were worth $8,569,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Axon Enterprise by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after acquiring an additional 53,060 shares in the last quarter. Geode Capital Management LLC grew its holdings in Axon Enterprise by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after acquiring an additional 35,544 shares in the last quarter. Baillie Gifford & Co. grew its holdings in Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after acquiring an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC increased its position in shares of Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after purchasing an additional 167,095 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Axon Enterprise by 326.9% in the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after purchasing an additional 1,179,038 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: RBC Capital Markets said Axon appears poised for bookings growth in the second quarter, supported by multiple emerging drivers, which points to continued demand for its public safety technology. Axon Enterprise Poised for Bookings Growth With Multiple Emerging Drivers, RBC Capital Markets Says
• Positive Sentiment: Axon appointed two new independent directors with deep technology and artificial intelligence experience, which could strengthen oversight and support future product and platform strategy. Axon Enterprise (AXON) Appoints Two Directors With Deep Tech And AI Experience
• Neutral Sentiment: Axon announced it will report second-quarter 2026 earnings on August 5, putting the stock in a wait-and-see mode ahead of results and guidance. Axon to Release Second Quarter 2026 Earnings on August 5, 2026
• Neutral Sentiment: Recent coverage notes Axon is attracting trader attention, but the articles mainly reiterate the same core facts rather than adding a major new catalyst. Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: One valuation-focused article argued that Axon may be fully priced on a cash flow basis, even if it still screens as reasonable on sales multiples, reinforcing concerns that the stock’s recent run has left limited upside if growth cools. Axon (AXON) Stock Could Be Fully Priced On Cash Flow Yet A Bargain On Sales
• Negative Sentiment: Another note highlighted rising costs and pressure on margins, even though Axon is trying to offset them through efficiency initiatives and aims for better profitability later on. Can Axon Enterprise Improve Margin Performance Amid Rising Costs?

Insiders Place Their Bets

In related news, Director Caitlin Elizabeth Kalinowski sold 564 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $478.97, for a total value of $270,139.08. Following the completion of the sale, the director owned 3,632 shares in the company, valued at $1,739,619.04. This represents a 13.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total transaction of $753,690.00. Following the completion of the sale, the insider owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. This trade represents a 4.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 58,989 shares of company stock valued at $30,527,983. 4.20% of the stock is owned by insiders.

Axon Enterprise Stock Down 3.8%

AXON opened at $491.49 on Thursday. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The stock has a market capitalization of $39.61 billion, a P/E ratio of 197.39, a price-to-earnings-growth ratio of 10.43 and a beta of 1.38. The business’s 50-day simple moving average is $478.98 and its 200-day simple moving average is $479.94.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.90 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business’s revenue was up 33.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.47 EPS. Analysts anticipate that Axon Enterprise, Inc will post 1.63 EPS for the current year.

Wall Street Analysts Forecast Growth

AXON has been the subject of several recent analyst reports. The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. Needham & Company LLC raised their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research note on Monday, July 6th. UBS Group decreased their price target on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Zacks Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 10th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $700.00 price objective on shares of Axon Enterprise in a report on Thursday, June 25th. Fifteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $725.25.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.